Literature DB >> 21463291

The impact of parent advocacy groups, the Internet, and social networking on rare diseases: the IDEA League and IDEA League United Kingdom example.

Angela P Black1, Marie Baker.   

Abstract

The development of the Internet and subsequent evolution of social networking has significantly changed the effectiveness of patient advocacy groups for rare diseases. The greatest degree of change has occurred at the patient level, with an increased ability of affected individuals to share experiences and support, and to raise public awareness. Other changes have occurred, not only in the way rare diseases are diagnosed, studied, and treated, but also in how they are addressed at the level of legislation and public policy. The International Dravet syndrome Epilepsy Action League (IDEA League) is the leading patient advocacy organization for Dravet syndrome and related genetic ion-channel epilepsy disorders (hereafter referred to as Dravet syndrome or severe myoclonic epilepsy of infancy, SMEI). The IDEA League's mission encompasses international support and outreach for patients and families, as well as collaboration with physicians, medical education, health care coordination, and research. The IDEA League is an excellent example of the impact of patient advocacy groups, the Internet, and social networking on the landscape of rare diseases. Wiley Periodicals, Inc.
© 2011 International League Against Epilepsy.

Entities:  

Mesh:

Year:  2011        PMID: 21463291     DOI: 10.1111/j.1528-1167.2011.03013.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  15 in total

Review 1.  The role of brain tumor advocacy groups.

Authors:  Michele Rhee; Paulius Mui; Carl Cadogan; Jonny Imerman; Sarah Lindsell; Lainey Titus Samant
Journal:  Curr Neurol Neurosci Rep       Date:  2014-04       Impact factor: 5.081

2.  Genetic Information-Seeking Behaviors and Knowledge among Family Members and Patients with Inherited Bone Marrow Failure Syndromes.

Authors:  Jada G Hamilton; Sadie P Hutson; Amy E Frohnmayer; Paul K J Han; June A Peters; Ann G Carr; Blanche P Alter
Journal:  J Genet Couns       Date:  2014-12-27       Impact factor: 2.537

Review 3.  The Promises and Perils of Social Media for Pediatric Rheumatology.

Authors:  Jonathan S Hausmann; Elissa R Weitzman
Journal:  Rheum Dis Clin North Am       Date:  2022-02       Impact factor: 2.670

Review 4.  The involvement of rare disease patient organisations in therapeutic innovation across rare paediatric neurological conditions: a narrative review.

Authors:  Christina Q Nguyen; Kristine Alba-Concepcion; Elizabeth E Palmer; Jackie L Scully; Nicole Millis; Michelle A Farrar
Journal:  Orphanet J Rare Dis       Date:  2022-04-18       Impact factor: 4.303

5.  A European network of email and telephone help lines providing information and support on rare diseases: results from a 1-month activity survey.

Authors:  Francois Houyez; Rosa Sanchez de Vega; Tuy Nga Brignol; Monica Mazzucato; Agata Polizzi
Journal:  Interact J Med Res       Date:  2014-05-05

6.  Attitudes towards Social Networking and Sharing Behaviors among Consumers of Direct-to-Consumer Personal Genomics.

Authors:  Sandra Soo-Jin Lee; Simone L Vernez; K E Ormond; Mark Granovetter
Journal:  J Pers Med       Date:  2013-10-14

7.  The involvement of patient organisations in rare disease research: a mixed methods study in Australia.

Authors:  Deirdre Pinto; Dominique Martin; Richard Chenhall
Journal:  Orphanet J Rare Dis       Date:  2016-01-12       Impact factor: 4.123

Review 8.  A systematic review of genetic skeletal disorders reported in Chinese biomedical journals between 1978 and 2012.

Authors:  Yazhou Cui; Heng Zhao; Zhenxing Liu; Chao Liu; Jing Luan; Xiaoyan Zhou; Jinxiang Han
Journal:  Orphanet J Rare Dis       Date:  2012-08-22       Impact factor: 4.123

9.  Key outcomes from stakeholder workshops at a symposium to inform the development of an Australian national plan for rare diseases.

Authors:  Caron Molster; Leanne Youngs; Emma Hammond; Hugh Dawkins
Journal:  Orphanet J Rare Dis       Date:  2012-08-10       Impact factor: 4.123

10.  Can the EVIDEM Framework Tackle Issues Raised by Evaluating Treatments for Rare Diseases: Analysis of Issues and Policies, and Context-Specific Adaptation.

Authors:  Monika Wagner; Hanane Khoury; Jacob Willet; Donna Rindress; Mireille Goetghebeur
Journal:  Pharmacoeconomics       Date:  2016-03       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.